Singapore, Singapore

Takeo Iida

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takeo Iida. Retrieved from https://idiyas.com/inventor/takeo-iida-b6yg2snj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Takeo Iida: Innovator in Cyclic Peptide Compounds

Introduction

Takeo Iida is a prominent inventor based in Singapore, known for his significant contributions to the field of cyclic peptide compounds. His innovative work focuses on compounds that have Kras inhibitory action, which has implications in cancer research and treatment.

Latest Patents

Takeo Iida holds a patent for a cyclic peptide compound that exhibits Kras inhibitory action. The patent details the discovery of cyclic peptide compounds that interact with Ras and the identification of non-natural amino acids that are useful for the production of these compounds. Furthermore, the invention highlights how these cyclic peptide compounds inhibit the binding between Ras and SOS, showcasing their potential therapeutic applications.

Career Highlights

Iida is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company. His work at Chugai has allowed him to explore and develop innovative solutions in the realm of peptide compounds. With a total of 1 patent, Iida's contributions are noteworthy in the scientific community.

Collaborations

Throughout his career, Takeo Iida has collaborated with esteemed colleagues such as Mikimasa Tanada and Koji Takano. These collaborations have further enriched his research and development efforts in the field of cyclic peptides.

Conclusion

Takeo Iida's work in cyclic peptide compounds represents a significant advancement in the understanding of Kras inhibitory actions. His innovative research continues to pave the way for potential breakthroughs in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…